Verigraft is a biotechnology company based in Gothenburg, Sweden, with roots in the renowned Karolinska Institute. Since 2014, the company has been at the forefront of industrialized tissue engineering and advanced regenerative medicine, built on groundbreaking basic science. Verigraft specializes in personalized tissues, focusing on areas such as cardiovascular and neuronal disease.

Their innovative technology allows for the creation of personalized tissue-engineered grafts, offering a paradigm shift in transplantation medicine. With a strategically focused R&D pipeline, Verigraft is set to bring a range of life-changing products to the global market. Their current and future offerings aim to help millions of patients suffering from incurable diseases, significantly improving their quality of life and reducing disability rates.

Located near Gothenburg University and Sweden's largest university hospital, Verigraft boasts state-of-the-art preclinical laboratories and offices. Led by a team of experienced scientists and entrepreneurs, Verigraft has garnered support and investment from Europe, Asia, and the US. Their unique technology is protected by strong patents and solid IP-protection, giving them a significant competitive advantage in the emerging field of regenerative medicine.

Verigraft's impactful solutions hold enormous potential to address the unmet medical needs of millions and provide substantial value to society by reducing sick leaves